Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04375761
Other study ID # DAIT-COVID-19-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2020
Est. completion date March 29, 2021

Study information

Verified date May 2024
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death. The purpose of this study is to: - Determine the prevalence of SARS-CoV-2 carrier status over time in children and parents - Determine the prevalence of antibody development over time in children and parents - Compare carrier status and antibody development for children with asthma and/or other atopic conditions (e.g. eczema) versus children without asthma and/or other atopic conditions - Investigate the presence of SARS-CoV-2 exposure in historical samples from enrolled participants


Description:

The study population will include children that are participants in NIH-funded cohort studies and their families (household contacts).The intent is to recruit families that have experience with the collection of respiratory samples. The objective of this surveillance study is to identify the rate of infection in children and what, if any effect, atopy has on the SARS-CoV-2 carrier status. The initial surveillance interval for participants will be 6 months and, depending upon the findings, may be extended. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed remotely via a smart phone, on-line, or phone communications at the time the biological samples are collected.


Recruitment information / eligibility

Status Completed
Enrollment 5599
Est. completion date March 29, 2021
Est. primary completion date March 29, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Household members who meet all of the following criteria are eligible for enrollment as study participants: - The index participant, defined as an individual who either is or has been a participant in an NIH-funded clinical research study from which information on respiratory conditions, including asthma, and other atopic and allergic diseases is available, is: - =21 years of age, and - Lives with caregiver(s). - The index participant and/or caregiver understands the study procedures and is willing to conduct these procedures at home; - Have the ability to use either a computer or a smart phone to link to and respond to the study questionnaires: --Exception: When the family is willing to speak with a study member to answer the questionnaires in the event of not having access to a computer or a smart phone. - The index participant and caregiver will reside in the United States, including Puerto Rico, for the duration of the study; - The index participant will live with the caregiver for at least 50% of the time for the duration of the study; - An English or Spanish speaker is available to: - Serve as the primary contact, and - As the person who will be responsible for the completion of questionnaires and the collection of study biological samples; and, - To participate as a sibling (of the index participant), must be under 21 years of age and live in the same home as the index participant and caregiver. Exclusion Criteria: -Past or current medical problems, which, in the opinion of the site investigator may: - Pose risks from participation in the study - Interfere with the participant's ability to comply with study requirements, or - Impact the quality or interpretation of the data obtained from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Collection of Biological Samples
Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
Symptom and Exposure Surveys
Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.

Locations

Country Name City State
United States Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site Aurora Colorado
United States Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site Aurora Colorado
United States Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site Boston Massachusetts
United States Boston Medical Center: Inner City Asthma Consortium (ICAC) Site Boston Massachusetts
United States Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site Boston Massachusetts
United States Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD) and Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC) Site Chicago Illinois
United States Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site Cincinnati Ohio
United States Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site Cincinnati Ohio
United States Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site Cincinnati Ohio
United States Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site Cincinnati Ohio
United States University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site Dallas Texas
United States Henry Ford Health System: Childhood Allergy Study (CAS) Site Detroit Michigan
United States Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site Detroit Michigan
United States Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site Detroit Michigan
United States University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site Madison Wisconsin
United States University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site Madison Wisconsin
United States Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site Nashville Tennessee
United States Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site New York New York
United States St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site Saint Louis Missouri
United States Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period Nasal samples were analyzed to determine whether a participant ever tested positive for SARS-CoV-2 or not over the course of the study. Kaplan-Meier was used to estimate survival probabilities at timepoints throughout the study. Participants were censored if they did not test positive for SARS-CoV-2 by the end of follow-up. The last positive nasal swab occurred at day 212. Baseline through end of study (24 or 28 weeks, depending on if a participant agreed to do the extension)
Secondary Percent of Index Participants and Their Household Contacts With Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period Included: Participants currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts.
Outcome definition: Detectable SARS-CoV-2-specific antibodies in serum biological specimen(s).
Up to Week 24
Secondary Number of Index Participants With SARS-CoV-2 Detection in Nasal Samples With Asthma and Other Atopic Disease Compared to Index Participants Without Atopic Disease Over the Study/Surveillance Period Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.
Testing method: Positive test result(s) for SARS-CoV-2 RNA in nasal samples.
Up to Week 24
Secondary Percent of Index Participants With Asthma and Other Atopic Disease With Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants Without Atopic Disease Over the Study/Surveillance Period Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.
Outcome definition: Detectable SARS-CoV-2-specific antibodies in serum biological specimen(s).
Through study completion, an average of 24 Weeks
Secondary Changes in the Nasal Transcriptome Associated With Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period Nasal samples of participants currently or previously enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts that test positive for SARS-CoV-2, will undergo transcriptome analysis.
Total RNA will be isolated for cDNA synthesis and amplification. Differential gene expression analysis be pursued.
Up to Week 24
Secondary Changes in the Nasal Transcriptome Associated With Detection of SARS-CoV-2 in Nasal Samples Among Index Participants With Asthma and Other Atopic Disease Compared to Index Participants Without Atopic Disease Over the Study/Surveillance Period Nasal samples of index participants that test positive for SARS-CoV-2 will be evaluated by transcriptome analysis. Differential gene expression analysis at different timepoints in the disease process will be analyzed.
Definition of index participant(s): Prior and/or current NIH-funded clinical research study participant(s) who fulfill inclusion criteria.
Up to Week 24
Secondary Symptoms Associated With Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period An analysis of symptoms associated with positive SARS-CoV-2 RNA tests in nasal samples will be conducted.
Included in analysis: Index participants and their household contacts.
Up to Week 24
Secondary Number of Index Participants With SARS-CoV-2 Detection in Nasal Samples Using Topical Steroids Compared to Index Participants That Are Not Using Topical Steroids Over the Study/Surveillance Period Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.
Tests: Positive for SARS-CoV-2 RNA in nasal samples
Up to Week 24
Secondary Number of Index Participants With SARS-CoV-2 Detection in Nasal Samples Using Topical, Oral, or Inhaled Steroids Compared to Index Participants That Are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.
Tests: Positive for SARS-CoV-2 RNA in nasal samples.
Up to Week 24
Secondary Analysis of Factors, Baseline and Prior History, for Possible Association With the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period An exploratory analysis will be conducted for detection of possible associations, focusing on baseline demographic and environment factors and/or history of bronchiolitis prior history with the cumulative incidence of SARS-CoV-2 detection in nasal samples Test: Positive for SARS-CoV-2 RNA in nasal samples. Baseline, Week 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A